Remodulin (Treprostinil Sodium) Patent Expiration, LOE Window & CMS Spending

Remodulin (Treprostinil Sodium) by United Therapeutics: FDA Orange Book core substance LOE 2028-12-15 (last listed 2029-03-29), 0 AB generics, $114.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUnited Therapeutics
FDA Application & PathwayN021272 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-12-15
Last Listed Patent or Exclusivity Date2029-03-29
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$114.6M
2024 Medicare Part D Spend$13.5M
2024 Medicaid Spend$101.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.